Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Date:1/25/2008

SAN DIEGO, Jan. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Merck & Co., Inc. initiated a Phase 1 clinical trial of a second generation oral niacin receptor agonist under a collaboration between the companies to discover drugs for the treatment of atherosclerosis and other disorders. The initiation of this trial does not trigger a milestone payment.

"We are very pleased with the progress of this collaboration investigating the therapeutic potential of niacin receptor agonists to treat atherosclerosis and other disorders. We are looking forward to the Phase 1 results and the continued progress of the program," said Jack Lief, Arena's President and Chief Executive Officer.

Arena also announced that preclinical investigation of MK-0354, a first generation niacin receptor agonist being evaluated for indications other than atherosclerosis, was discontinued for compound specific reasons.

About Atherosclerosis

Atherosclerosis is characterized by the collection of fatty material deposits, such as cholesterol, along artery walls. This fatty material thickens, hardens, and may eventually block the arteries, adversely affecting blood flow and increasing the risk of heart attack and stroke over time. The American Heart Association estimates that atherosclerosis accounts for nearly 75% of all deaths from cardiovascular disease. HDL cholesterol, commonly known as the "good" cholesterol, can help clear the fatty deposits from the walls of blood vessels and transport cholesterol to the liver for processing and removal from the body. Drugs that can influence the levels of HDL cholesterol, or "good" cholesterol, may potentially provide clinical benefits to patients by reducing the
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
2. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
3. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
4. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2
... Corporation, (OTC Bulletin Board: CDXC) a leader in ... financial results for the 2008 Fiscal Year. On ... Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced ... $0.07 per share for the twelve months ended ...
... April 3 InterMune, Inc. (Nasdaq: ITMN ) ... Officer of InterMune, will present at the Canaccord Adams Hepatitis ... To access a live audio webcast of the presentation, ... investor relations page of InterMune,s corporate website at www.intermune.com ...
... Inc. (Nasdaq: TPTX ) today announced that on ... Qualifications Department of the Nasdaq Stock Market ("Nasdaq") notifying the ... in its Annual Report on Form 10-K for the year ... the minimum stockholders, equity requirement of $10 million for continued ...
Cached Biology Technology:ChromaDex Announces 2008 Year End Financial Results 2ChromaDex Announces 2008 Year End Financial Results 3TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements 2
(Date:7/11/2014)... the Department of Energy,s Oak Ridge National Laboratory ... R&D Magazine in recognition of the year,s top ... tremendous value of our National Labs," said Secretary ... the National Labs continues to help our nation ... and technological innovations necessary to remain globally competitive." ...
(Date:7/11/2014)... release is available in German . ... a method that uses the refraction of X-rays through ... images produced with this method are often of much ... in the team of Prof. Franz Pfeiffer are particularly ... and therapy including X-ray phase-contrast imaging. One main ...
(Date:7/11/2014)... with other group members to reduce aggression and gain ... strategy for grooming activities shows a certain pattern across ... scientific journal Biology Letters . , Grooming between ... without ulterior motives. To be groomed has hygienic benefits ... another individual can provide access to infants, mating opportunities ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... December 15, 2009 Signal Hill, CA Tom ... public and president of Bowman Global Change, has developed ... the fourth Intergovernmental Panel on Climate Change (IPCC) report ... to the authentic scientific information they need to make ...
... , REDWOOD CITY, Calif., Dec. ... and authentication solutions, today announced an agreement with IBM ... fingerprint technology on IBM SurePOS 500 retail systems. The ... easily and quickly identify users so that specific transactions ...
... ... Dec. 8, 2009 National Instruments (Nasdaq: NATI ), ... a leader and pioneer in manufacturing automation using robotics technology, ... technology with DENSO robotic arms. The collaboration increases productivity and ...
Cached Biology News:Bowman creates graphic translation of climate change data 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5
...
... Crystal / Mount is the standard water ... designed especially for the permanent preservation of ... It is easy to use and exhibits ... the first aqueous mounting medium that permits ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
Request Info...
Biology Products: